呼吸器合胞体ウイルス下気道感染症で入院した日本人小児におけるALX-0171の評価

基本情報

NCT ID: NCT03418571
ステータス: 中止
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 15
治験依頼者名: Ablynx, a Sanofi company

概要

This was a randomized, double-blind, multicenter, Phase II study (NCT03418571) designed to support the selection of an optimal dose of inhaled ALX-0171 for further clinical development, taking ethnicity into consideration. Based on the results of the Phase IIb dose-ranging study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study.

対象疾患

Respiratory Syncytial Virus Lower Respiratory Tract Infection

介入

ALX-0171 1.5 mg/kg(BIOLOGICAL)

Placebo(OTHER)

依頼者（Sponsor）

Ablynx, A Sanofi Company(INDUSTRY)